Eisai Clinical Trials

Study of Lenvatinib (E7080) in Participants With Advanced Hepatocellular Carcinoma (HCC)


Study Overview

Jul 2009 - Jun 2014
Hepatocellular Carcinoma (HCC)
Primary efficacy endpoint was not applicable in Phase 1. The primary efficacy endpoint in Phase 2 was time to progression (TTP).

  • Males and females (age 20 to 80 years)

  • Completed

  • Phase 1 / 2

  • Japan, Korea, Republic of See more


CSR Synopsis

Download PDF

Lay Summary

Download PDF
Publication reference citation

Ikeda K et al. Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma. J Gastroenterol. 2017 Apr;52(4):512-519. DOI: 10.1007/s00535-016-1263-4

Data Sharing

ClinicalStudyDataRequest.com (CSDR) is a multi sponsor site through which qualified researchers who wish to access clinical trial data and associated information in order to conduct further research can submit their research proposal or enquiry.

Redacted documents are available upon request for this study.

Document type Availability
Sample CRF
Full CSR